Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Oliver Higuera"'
Autor:
D. Pérez Parente, Oliver Higuera, A.L. Ortega Granados, Pedro Ruiz-Gracia, L. Vilà, A. Moreno Paul, L. Sáenz Cuervo-Arango
Publikováno v:
Journal of Thoracic Oncology. 16:S521-S522
Autor:
Olga Pernía, Rocío Rosas, Ángel Diaz Lagares, Olga Vera Puente, Patricia Cruz Castellanos, Julia Jimenez, Isabel Esteban, Javier de Castro, Oliver Higuera, Inmaculada Ibáñez De Cáceres, Itsaso Losantos, Tatiana Juste
Publikováno v:
Cancer Research. 81:2095-2095
Background: Non-small cell lung cancer (NSCLC) represents the 80-85% of the lung cancer. Cisplatin-based chemotherapy is the paradigm of NSCLC treatment; however, it also induces de novo DNA hyper methylation that is associated with gene expression r
Autor:
J. De Castro Carpeno, Oliver Higuera, S. Martínez Recio, L. Gutiérrez Sainz, D. Sanchez Cabrero, Isabel Esteban, D. Viñal, F. Arias Lotto, J. Villamayor, Patricia Cruz
Publikováno v:
Journal of Thoracic Oncology. 14:S1106-S1107
Autor:
A. Pertejo, J. Villamayor, J.L. Torres, J. Ramón, Oliver Higuera, S. Martinez, J. De Castro Carpeno, D. Sanchez Cabrero, L. Gutierrez, Isabel Esteban, P. Perez, Pedro Mateos Cruz, D. Viñal
Publikováno v:
Journal of Thoracic Oncology. 14:S1027
Autor:
Isabel Esteban, A. Pertejo, D. Viñal, P. Perez, J. Villamayor, J. De Castro Carpeno, S. Martinez, D. Sanchez Cabrero, L. Gutierrez, J.L. Torres, J. Ramón, Oliver Higuera, Pedro Mateos Cruz
Publikováno v:
Journal of Thoracic Oncology. 14:S1024
Autor:
S. Martinez, D. Sanchez Cabrero, J. De Castro Carpeno, P. Perez, L. Gutierrez, J.L. Torres, Isabel Esteban, J. Ramón, D. Viñal, Pedro Mateos Cruz, Oliver Higuera, A. Pertejo, J. Villamayor
Publikováno v:
Journal of Thoracic Oncology. 14:S1027
Autor:
Lucía Sáenz Cuervo-Arango, Laia Vilà, Silverio Ros Martínez, Amaia Moreno Paul, Diego Pérez Parente, Pedro Ruiz Gracia, Oliver Higuera Gómez, Ana Laura Ortega Granados
Publikováno v:
BASE-Bielefeld Academic Search Engine
Cancer Management and Research
Cancer Management and Research
Purpose Identifying patient characteristics that define a worse disease prognosis or "high tumor burden" (HTB) status is essential for clinical decision-making and treatment selection in metastatic non-small cell lung cancer (mNSCLC). We aimed to def
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327ca0eb7c8e6e3b9f35ef3e380c0dc4
https://www.dovepress.com/high-tumor-burden-in-metastatic-non-small-cell-lung-cancer-defining-th-peer-reviewed-fulltext-article-CMAR
https://www.dovepress.com/high-tumor-burden-in-metastatic-non-small-cell-lung-cancer-defining-th-peer-reviewed-fulltext-article-CMAR